Cardiovascular risk factors in adult Malawians on long-term antiretroviral therapy

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 105, Issue 11, 2011, Pages 644-649

  Muronya, William ^a   Sanga, Esther ^a   Talama, George ^a   Kumwenda, Johnstone J ^a   Van Oosterhout, Joep J ^a  

^a UNIVERSITY OF MALAWI   (Malawi)

Author keywords

ART; Cardiovascular; HIV; Malawi; Risk factors

Indexed keywords

ALCOHOL; ANTIRETROVIRUS AGENT; CHOLESTEROL; EFAVIRENZ; GLUCOSE; LAMIVUDINE; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

ADULT; AGED; ALCOHOL CONSUMPTION; ANTIVIRAL THERAPY; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CROSS-SECTIONAL STUDY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOOD INTAKE; FRUIT; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALAWI; MALE; OBESITY; PHYSICAL ACTIVITY; RISK ASSESSMENT; SEDENTARY LIFESTYLE; TREATMENT DURATION; VEGETABLE; WAIST HIP RATIO;

ADULT; AGE FACTORS; AGED; ANTI-HIV AGENTS; ATHEROSCLEROSIS; CROSS-SECTIONAL STUDIES; FEMALE; FOOD HABITS; HIV INFECTIONS; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; MALAWI; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OVERWEIGHT; RISK FACTORS; SEDENTARY LIFESTYLE; URBAN HEALTH; URBAN POPULATION; WAIST-HIP RATIO;

EID: 80054064123     PISSN: 00359203     EISSN: 18783503     Source Type: Journal    
DOI: 10.1016/j.trstmh.2011.07.016     Document Type: Article

References (23)

1. Harries A.D., Schouten E.J., Libamba E. Scaling up antiretroviral treatment in resource-poor settings. Lancet 2006, 367:1870-1872.
2. Libamba E., Makombe S.D., Harries A.D., Schouten E.J., Yu J.K.L., Pasulani O., et al. Malawi's contribution to "3 by 5": achievements and challenges. Bull World Health Organ 2007, 85:156-160.
3. Walensky R.P., Paltiel A.D., Losina E., Mercincavage L.M., Schackman B.R., Sax P.E., et al. The survival benefits of AIDS treatment in the United States. J Infect Dis 2006, 194:11-19.
4. Jahn A., Floyd S., Crampin A.C., Mwaungulu F., Mvula H., Munthali F., et al. Population-level effect of HIV on adult mortality and early evidence of reversal after introduction of antiretroviral therapy in Malawi. Lancet 2008, 371:1603-1611.
5. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003, 349:1993-2003. The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group.
6. Stein J.H. Cardiovascular risks of antiretroviral therapy. N Engl J Med 2006, 356:1773-1775.
7. Calza L., Manfredi R., Verucchi G. Myocardial infarction risk in HIV-infected patients: epidemiology, pathogenesis, and clinical management. AIDS 2010, 24:789-802.
8. CD4 count-guided interruption of antiretroviral treatment. N Engl J Med 2006, 355:2283-2296. The Strategies for Management of Antiretroviral Therapy (SMART) Study Group.
9. Class of Antiretroviral Drugs and the Risk of Myocardial Infarction. N Engl J Med 2007, 356:1723-1735. The DAD Study Group.
10. Holmberg S.D., Moorman A.C., Williamson J.M., Tong T.C., Ward D.J., Wood K.C., et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002, 360:1747-1748.
11. Bozzette S.A., Ake C.F., Tam H.K., Chang S.W., Louis T.A. Cardiovascular and cerebrovascular events in patients treated for Human Immunodeficiency Virus Infection. N Engl J Med 2003, 348:702-710.
12. WHO. Department of Chronic Diseases and Health Promotion. Preventing chronic diseases: a vital investment. WHO Global Report. Geneva: World Health Organization 2005.
13. Ministry of Health, Malawi, WHO Malawi. Malawi national STEPS survey for chronic non-communicable diseases and their risk factors. Final report. [accessed 30 December 2010]. http://www.who.int/chp/steps/Malawi_2009_STEPS_Report.pdf.
14. Wohl D.A., McComsey G., Tebas P., Brown T.T., Glesby M.J., Reeds D., et al. Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy. Clin Infect Dis 2006, 43:645-653.
15. Wand H., Calmy A., Carey D.L., Samaras K., Carr A., Law M.G., et al. Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. AIDS 2007, 21:2445-2453.
16. Buchacz K., Weidle P.J., Moore D., Were W., Mermin J., Downing R., et al. Changes in lipid profile over 24 months among adults on first-line highly active antiretroviral therapy in the home-based AIDS care program in rural Uganda. J Acquir Immune Defic Syndr 2008, 47:304-311.
17. Lungu, M., Malisita K, van Oosterhout JJ. ART Clinic Queen Elizabeth Central Hospital Quarterly Report Q1-2010. Blantyre: Ministry of Health; 2010.
18. Msyamboza K.P., Ngwira B., Dzowela T., Mvula C., Kathyola D., Harries A.D., et al. The burden of selected chronic non-communicable diseases and their risk factors in Malawi: Nationwide STEPS Survey. PLoS ONE 2011, 6:e20316.
19. Salami A.K., Akande A.A., Olokoba A.B. Serum lipids and glucose abnormalities in HIV/AIDS patients on antiretroviral therapies. West Afr J Med 2009, 28:10-15.
20. Mutimura E., Stewart A., Rheeder P., Crowther N.J. Metabolic function and the prevalence of lipodystrophy in a population of HIV-infected African subjects receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2007, 46:451-455.
21. Mercier S., Gueye N.F., Cournil A., Fontbonne A., Copin N., Ndiaye I., et al. Lipodystrophy and metabolic disorders in HIV-1-infected adults on 4- to 9-year antiretroviral therapy in Senegal: a case-control study. J Acquir Immune Defic Syndr 2009, 51:224-230.
22. Craig S.R., Amin R.V., Russell D.W., Paradise N.F. Blood cholesterol screening. influence of fasting state on cholesterol results and management decisions. J Gen Intern Med 2000, 15:395-399.
23. Jaquet A., Ekouevi D.K., Aboubakrine M., Bashi J., Messou E., Maiga M., et al. Tobacco use and its determinants in HIV-infected patients on antiretroviral therapy in West African countries. Int J Tuberc Lung Dis 2009, 13:1433-1439.